SUBSCRIBE
SUBSCRIBE

Incyte

NEWS
Business
MacroGenic Scores $900M Checkpoint PD-1 R&D Deal With Incyte
Incyte picked up MGA012 and the exclusive rights to develop the drug worldwide.
October 25, 2017
 · 
2 min read
 · 
Alex Keown
Sotera Employees Misappropriated Masimo Trade Secr
Policy
The IDO Battle Gets Ugly
Incyte has been at the forefront of the IDO race with its candidate epacadostat.
October 23, 2017
 · 
1 min read
 · 
Karl Thiel
Policy
Incyte Claims Flexus Lured Away CSO and Its IDO Secrets, Then Sold Itself to Bristol-Myers in $1.25B Deal
Incyte has levelled charges of stealing company secrets against the founders of Flexus Biosciences over the hiring of Incyte’s former CSO who had access to Incyte’s scientific research.
October 16, 2017
 · 
2 min read
 · 
Alex Keown
Business
The Secret To Booming Incyte’s Success
October 11, 2017
 · 
1 min read
Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda
Drug Development
Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda
August 31, 2017
 · 
3 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
Policy
Blood Clot Fears Delay Eli Lilly, Incyte’s Potential Rheumatoid Arthritis Blockbuster, Stocks Fall
July 25, 2017
 · 
3 min read
Deals
Why Incyte Is Still A Good Backup Plan For Gilead
July 14, 2017
 · 
1 min read
Business
Gilead’s Rumored M&A Target Incyte Doubled CEO’s Pay Package in 2016
April 18, 2017
 · 
1 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
FDA
FDA Just Rejected Eli Lilly, Incyte’s Rheumatoid Arthritis Drug Baricitinib
April 14, 2017
 · 
2 min read
Load More
AWARDS
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS
Press Releases
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
June 26, 2026
 · 
11 min read
Press Releases
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
June 19, 2026
 · 
9 min read
Press Releases
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
June 15, 2026
 · 
11 min read
Press Releases
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
June 15, 2026
 · 
14 min read
Press Releases
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
June 15, 2026
 · 
12 min read
Press Releases
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
June 8, 2026
 · 
8 min read
Press Releases
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
June 4, 2026
 · 
8 min read
Press Releases
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
June 1, 2026
 · 
13 min read
Press Releases
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
 · 
1 min read
Press Releases
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
May 20, 2026
 · 
5 min read
Load More